MEDIANA Co.Ltd (041920) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of MEDIANA Co.Ltd KRW 5,424, price KRW 8,910, upside -39.1%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch MEDIANA Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3,733 KRW – 28,650 KRW · fair‑value band 4,029 KRW – 7,312 KRW · the 8,910 KRW price screens above the 5,424 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow MEDIANA Co.Ltd in your weekly email
Every Wednesday you see whether MEDIANA Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mediana Co.,Ltd, together with its subsidiaries, develops, manufactures, and sells medical devices in South Korea. It offers patient monitors, vital signs monitors, AEDs, monitors/defibrillators, fetal products, body composition analyzers, central monitoring systems, face masks, spot checks and monitors, pulse oximeters, and physio modules.
Show more
Mediana Co.,Ltd, together with its subsidiaries, develops, manufactures, and sells medical devices in South Korea. It offers patient monitors, vital signs monitors, AEDs, monitors/defibrillators, fetal products, body composition analyzers, central monitoring systems, face masks, spot checks and monitors, pulse oximeters, and physio modules. The company also exports ODM and own branded products through agencies in approximately 80 countries. Mediana Co.,Ltd was founded in 1993 and is headquartered in Wonju-si, South Korea.
Stock analysis
MEDIANA Co.Ltd (041920) currently trades at 8,910 KRW, while our model-based Fair Value estimate is 5,424 KRW, implying the stock looks roughly 64.3% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 5,654 KRW per share, and 0 of the 26 models we run sit above the 8,910 KRW price.
Bear case: the Earnings-Based group reads lowest at 2,058 KRW, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 4,029 KRW (bear) to 7,312 KRW (bull), the price of 8,910 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
MEDIANA Co.Ltd reported revenue of 64.9B KRW in FY2025 versus 56.8B KRW in FY2021, a compound +3.4%/yr. Reported net income was 5.3B KRW in FY2025, compounding −11.9%/yr from FY2021.
Key figures
Market cap 180B KRW (≈ $126M) · P/S ratio 2.77 · Dividend yield 0.2% · Net margin 8.1% · Return on equity 395% · Return on assets (EBIT) 6.6% · Operating margin 15.6% · Revenue (TTM) 65.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 69% below its 52-week high and 83% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −39%, 041920 screens richer than that median.
Fair Value models
Bear 4,029 KRWFair Value 5,424 KRWBull 7,312 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+13.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Start year 2020 (pandemic). Over 10 years: +3.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−12.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.3%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12% vs −5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 9%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +10.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2623 stocks
Beats the sector median on 7/9 measures
Overall it ranks above its sector peers.
Valuation
Quality Score61 · Above median
Fair Value upside−39% · Below median
Profitability
Return on equity (TTM)395% · Top 25%
Return on assets7% · Top 25%
Net margin (TTM)22% · Top 25%
Operating margin (TTM)16% · Above median
Growth and dividend
Revenue growth60% · Top 25%
Dividend yield (TTM)0.2% · Bottom 25%
Valuation Multiplesvs Health Care median · lower = cheaper
P/FCF0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)100· sector 21
PAST (return on equity)100· sector 13
HEALTH (low debt)100· sector 96
DIVIDEND (yield)4· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MEDIANA Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/041920
Frequently asked questions
Is MEDIANA Co.Ltd (041920) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 5,424 KRW versus a price of 8,910 KRW, about −39% upside (overvalued).
What is the fair value of 041920?
Our model-based fair value for MEDIANA Co.Ltd is 5,424 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,910 KRW.
What is the quality score of 041920?
MEDIANA Co.Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDIANA Co.Ltd (041920)?
Our model-based price target is the fair value of 5,424 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 4,029 KRW, optimistic scenario 7,312 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDIANA Co.Ltd stock forecast for 2026?
Our models put fair value at 5,424 KRW, about −39% upside versus a price of 8,910 KRW (overvalued). Cautious scenario 4,029 KRW, optimistic scenario 7,312 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MEDIANA Co.Ltd (041920)?
MEDIANA Co.Ltd reported trailing-twelve-month revenue of about 65.0B KRW (latest available figure, as of Sep 24, 2026).
Does MEDIANA Co.Ltd pay a dividend?
MEDIANA Co.Ltd currently shows a dividend yield of about 0.22% relative to its recent price (as of Sep 24, 2026).
What growth is priced into MEDIANA Co.Ltd (041920)?
For today's price to be fair in a discounted-cash-flow model, MEDIANA Co.Ltd would have to grow free cash flow by +12.4 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 041920 use?
Our models discount MEDIANA Co.Ltd at 13.1 %: a base by market capitalisation (micro), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MEDIANA Co.Ltd that is +12.4 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has MEDIANA Co.Ltd (041920) delivered so far?
Over the past 5 years revenue at MEDIANA Co.Ltd grew -0.8 % a year. The price currently implies +12.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MEDIANA Co.Ltd (041920) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into MEDIANA Co.Ltd (+12.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MEDIANA Co.Ltd (041920)?
The free-cash-flow yield on the price is 2.98 %: that much free cash flow MEDIANA Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MEDIANA Co.Ltd (041920)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDIANA Co.Ltd it is 5,424 KRW per share (as of Sep 24, 2026), against a price of 8,910 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is MEDIANA Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 041920 trades above its calculated fair value: price 8,910 KRW, fair value 5,424 KRW, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 041920?
No. The price is what the market pays today (8,910 KRW); the fair value is what the company's own numbers justify (5,424 KRW). For MEDIANA Co.Ltd the two are 3,486 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDIANA Co.Ltd worth?
The market values MEDIANA Co.Ltd at about 180B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,910 KRW; our models calculate a fair value of 5,424 KRW per share.
What do the bullish and bearish scenarios say about 041920?
Our models span a range for MEDIANA Co.Ltd: cautious scenario 4,029 KRW, base 5,424 KRW, optimistic 7,312 KRW per share (as of Sep 24, 2026, price 8,910 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MEDIANA Co.Ltd (041920)?
Balance-sheet figures for MEDIANA Co.Ltd (as of Sep 24, 2026): return on equity 395.5%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 041920 from its 52-week high?
MEDIANA Co.Ltd trades at 8,910 KRW, about 69% below its 52-week high of 28,650 KRW and 83% above the low of 4,870 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 5,424 KRW is for.
Which stocks are comparable to MEDIANA Co.Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Meta Biomed Co, Sewoon Medical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDIANA Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 8,910 KRW, calculated fair value 5,424 KRW (−39%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 041920 calculated?
We run MEDIANA Co.Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5,424 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. MEDIANA Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDIANA Co.Ltd (041920)?
The closing price on Sep 23, 2026 was 8,910 KRW. Our model-based fair value is 5,424 KRW, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDIANA Co.Ltd right now?
The price sits above even our optimistic bull case (7,312 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (4,029 KRW to 7,312 KRW) leaves room in how you read the outcome.
Key figures of MEDIANA Co.Ltd
How large is the market capitalisation of MEDIANA Co.Ltd (041920)?
The market capitalisation of MEDIANA Co.Ltd is 180B KRW (≈ $126M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDIANA Co.Ltd (041920)?
The price-to-sales ratio of MEDIANA Co.Ltd is 2.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of MEDIANA Co.Ltd (041920)?
The dividend yield of MEDIANA Co.Ltd is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MEDIANA Co.Ltd (041920)?
The net margin of MEDIANA Co.Ltd is 8.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDIANA Co.Ltd (041920)?
The return on equity (ROE) of MEDIANA Co.Ltd is 395% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDIANA Co.Ltd (041920)?
On an EBIT basis the return on assets of MEDIANA Co.Ltd is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDIANA Co.Ltd (041920)?
The operating margin of MEDIANA Co.Ltd is 15.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDIANA Co.Ltd (041920)?
Revenue at MEDIANA Co.Ltd is growing +59.8% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDIANA Co.Ltd (041920)?
Earnings per share at MEDIANA Co.Ltd are growing +202% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch MEDIANA Co.Ltd in the live analysis
One click puts MEDIANA Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
